The objective of this Surveillance is to verify the following subject matters concerning Tofacitinib (Xeljanz) under general practice.
1) Occurrence of adverse reactions, factors that may potentially affect safety and efficacy 2） Long-term safety (particularly, malignant tumors and serious infections) and efficacy
Occurrences of malignant tumors and serious infections will be compared with a control group.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01932372?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
